Healthcare / Medical Instruments & SuppliesTokyo
$808.00
-17.00 (-2.06%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $126.2M · quality 42.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.7B
P/E
8.2x
↓EV/EBITDA
5.2x
↓ROE
9.1%
↑Gross Margin
31.4%
↓Debt/Equity
0.59
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.8%
FCF CAGR
—
FCF margin
-14.0%
FCF / Net income
-2.54x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.11B · net income $780.6M · FCF $-1.98B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.11B | $14.11B | $13.00B | $12.88B | $11.92B |
| Net Income | $780.6M | $780.6M | $584.1M | $748.2M | $589.1M |
| EBITDA | $1.77B | $1.77B | $1.39B | $1.77B | $1.47B |
| EPS | 109.77 | 109.77 | 82.13 | 105.22 | 82.84 |
| Gross Margin | 31.4% | 31.4% | 30.8% | 31.7% | 31.1% |
| Operating Margin | 7.6% | 7.6% | 6.0% | 7.5% | 5.1% |
| Net Margin | 5.5% | 5.5% | 4.5% | 5.8% | 4.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.59 | 0.59 | 0.38 | 0.43 | 0.52 |
| Current Ratio | 1.82 | 1.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.98B | $-1.98B | $126.2M | $574.0M | $-7.5M |
| Returns | |||||
| ROE | 9.1% | 9.1% | 7.1% | 10.2% | 9.1% |
| Valuation | |||||
| P/E | 8.18 | 8.18 | 9.23 | 7.91 | 10.92 |
| EV/EBITDA | 5.24 | 5.24 | 4.97 | 4.19 | 5.76 |
| P/B | 0.67 | 0.67 | 0.65 | 0.81 | 0.99 |
| Growth & Yield | |||||
| Revenue Growth | 8.6% | 8.6% | 0.9% | 8.0% | — |
| EPS Growth | 33.7% | 33.7% | -21.9% | 27.0% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-13.2%
EPS terminal req.
$71.70
Spread vs growth
46.9%
5Y implied EPS CAGR
-4.6%
EPS terminal req.
$86.75
Spread vs growth
38.3%
10Y implied EPS CAGR
2.4%
EPS terminal req.
$139.72
Spread vs growth
31.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.8%
Start / end P/E
9.7x → 7.4x
EPS bridge
82.13 → 109.77
Residual
-8.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.